Examining the risk of cardiovascular disease in patients with psoriasis: A critical review

Journal of Cutaneous Medicine and Surgery

Volumn 17, Issue 2, 2013, Pages 89-105

  Papp, Kim ^a,b,c   Poulin, Yves ^a,b,c   Vieira, Andrew ^a,b,c  

^a PROBITY MEDICAL RESEARCH   (Canada)

^b Centre Dermatologique du Quebec Metropolitain   (Canada)

^c Amgen Canada Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MORBIDITY; OBESITY; PATIENT ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; REVIEW; SMOKING;

CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; METABOLIC SYNDROME X; OBESITY; ODDS RATIO; PREVALENCE; PSORIASIS; RISK FACTORS; SMOKING;

EID: 84876940232     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2012.11126     Document Type: Review

References (90)

1. Canadian Dermatology Association. Psoriasis. 2009. Available at: http://www.dermatology.ca/patients-public/info-patients/psoriasis/index.html (accessed August 3, 2011).
2. National Psoriasis Foundation. National psoriasis foundation. About psoriasis: statistics. 2011. Available at: http://www.psoriasis. org/page.aspx?pid5372 (accessed August 3, 2011).
3. National Psoriasis Foundation. Patents & youth: facts about psoriasis. 2011. Available at: http://psoriasis.org/learn-forteens-facts (accessed August 3, 2011).
4. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-30, doi:10.1084/jem.20030451.
5. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445:648-51, doi:10.1038/nature05505.
6. Bonifati C, Carducci M, Cordiali FP, et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationships with disease severity. Clin Exp Dermatol 1994;19:383-7, doi:10.1111/j.1365-2230.1994. tb02687.x.
7. Armstrong AW, Voyles SV, Armstrong EJ, et al. A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp Dermatol 2011;20:544-9, doi:10.1111/j.1600-0625.2011.01308. x.
8. Kimball AB, Guerin A, Latremouille-Viau D, et al. Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis. Am J Med 2010;123:350-7, doi:10.1016/j.amjmed. 2009.08.022.
9. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41, doi:10.1001/jama.296.14.1735.
10. Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009;129:2411-8, doi:10.1038/jid.2009.112.
11. Prodanovich S, Kirsner RS, Kravetz JD, et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009;145:700-3, doi:10.1001/archdermatol.2009.94.
12. Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003;30:1196-202.
13. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003;30:36-40.
14. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303-7, doi:10.1161/01.CIR. 0000054612.26458.B2.
15. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15, doi:10.1093/oxfordjournals.aje.a009122.
16. Hak AE, Karlson EW, Feskanich D, et al. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the Nurses' Health Study. Arthritis Rheum 2009;61:1396-402, doi:10.1002/art.24537.
17. Fischer LM, Schlienger RG, Matter C, et al. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 2004;93:198-200, doi:10.1016/j.amjcard.2003. 09.037.
18. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008;159:895-902, doi:10.1111/j.1365-2133.2008.08707.x.
19. Xiao J, Chen LH, Tu YT, et al. Prevalence of myocardial infarction in patients with psoriasis in central China. J Eur Acad Dermatol Venereol 2009;23:1311-5, doi:10.1111/j.1468-3083.2009.03318.x.
20. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55:829-35, doi:10.1016/j.jaad.2006.08.040.
21. Al Mutairi N, Al Farag S, Al Mutairi A, et al. Comorbidities associated with psoriasis: an experience from the Middle East. J Dermatol 2010;37:146-55, doi:10.1111/j.1346-8138.2009.00777.x.
22. Armstrong AW, Lin SW, Chambers CJ, et al. Psoriasis and hypertension severity: results from a case-control study. PLoS One 2011;6:e18227, doi:10.1371/journal.pone.0018227.
23. Augustin M, Reich K, Glaeske G, et al. Co-morbidity and agerelated prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 2010;90:147-51, doi:10.2340/00015555-0770.
24. Choi WJ, Park EJ, Kwon IH, et al. Association between psoriasis and cardiovascular risk factors in Korean patients. Ann Dermatol 2010;22:300-6, doi:10.5021/ad.2010.22.3.300.
25. Driessen RJ, Boezeman JB, Van De Kerkhof PC, et al. Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies. J Dermatolog Treat 2009;20: 42-7, doi:10.1080/09546630802225702.
26. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007;157:68-73, doi:10.1111/j.1365-2133.
27. Mallbris L, Granath F, Hamsten A, et al. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006;54:614-21, doi:10.1016/j.jaad.2005.11.1079.
28. Schmitt J, Ford DE. Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. J Eur Acad Dermatol Venereol 2010;24:885-92, doi:10.1111/j.1468- 3083.2009.03537.x.
29. Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol 2008;7:373-7.
30. Gisondi P, Farina S, Giordano MV, et al. Usefulness of the Framingham Risk Score in patients with chronic psoriasis. Am J Cardiol 2010;106:1754-7, doi:10.1016/j.amjcard.2010.08.016.
31. Kimball AB, Robinson D Jr, Wu Y, et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology 2008;217:27-37, doi:10.1159/000121333.
32. Patel RV, Shelling ML, Prodanovich S, et al. Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature. J Gen Intern Med 2011;98:1374-8.
33. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143:1493-9, doi:10.1001/archderm.143.12. 1493.
34. Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010;31:1000- 6, doi:10.1093/eurheartj/ ehp567.
35. Prey S, Paul C, Bronsard V, et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol 2010;24 Suppl 2:23- 30, doi:10.1111/j.1468-3083. 2009.03564.x.
36. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-6, doi:10.1016/0190-9622(95) 91336-X.
37. Wolf N, Quaranta M, Prescott NJ, et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 2008;45:114-6, doi:10.1136/jmg. 2007.053595.
38. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125:61-7, doi:10.1111/j.0022-202X.2005.23681.x.
39. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007;167:1670-5, doi:10.1001/archinte.167.15.1670.
40. Cerman AA, Bozkurt S, Sav A, et al. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol 2008;159: 820-6, doi:10.1111/j.1365-2133.2008.08742.x.
41. Kaur S, Zilmer K, Kairane C, et al. Clear differences in adiponectin level and glutathione redox status revealed in obese and normalweight patients with psoriasis. Br J Dermatol 2008;159:1364-7, doi:10.1111/j.1365-2133.2008. 08759.x.
42. Lin HW, Wang KH, Lin HC, et al. Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population- based study in Taiwan. J Am Acad Dermatol 2011;64:495- 501, doi:10.1016/j.jaad.2010.01.050.
43. Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested casecontrol analysis. Arthritis Rheum 2008;58:2612-21, doi:10.1002/art.23811.
44. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225-30, doi:10.1023/B:EJEP.0000020447.59150.f9.
45. Stern RS, Huibregtse A. Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk. J Invest Dermatol 2011;131:1159-66, doi: 10.1038/jid.2010.399.
46. Gelfand JM, Mehta NN, Langan SM. Psoriasis and cardiovascular risk: strength in numbers, part II. J Invest Dermatol 2011;131: 1007-10, doi:10.1038/jid.2011.32.
47. Brauchli YB, Jick SS, Miret M, et al. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol 2009;160:1048-56, doi:10.1111/j.1365-2133.2008.09020.x.
48. Wakkee M, Meijer W, Neumann HA, et al. Psoriasis may not be an independent predictor for the use of cardiovascular and antidiabetic drugs: a 5-year prevalence study. Acta Derm Venereol 2009;89:476-83, doi:10.2340/ 00015555-0688.
49. Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol 2010;130:962-7, doi:10.1038/jid.2009.321.
50. Gelfand JM, Azfar RS, Mehta NN. Psoriasis and cardiovascular risk: strength in numbers. J Invest Dermatol 2010;130:919-22, doi:10.1038/jid.2010.12.
51. Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:576-82, doi:10.1136/ard.2010.129916.
52. Wu J. The effect of tumor necrosis factor-alpha inhibitors on the risk of myocardial infarction in patients with psoriasis [abstract]. 69th Annual Meeting of American Academy of Dermatology; 2011; New Orleans, LA.
53. Westlake SL, Colebatch AN, Baird J, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2011;50:518-31, doi:10.1093/rheumatology/keq316.
54. Barnabe C, Martin BJ, Ghali WA. Systematic review and metaanalysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011;63:522-9, doi:10.1002/acr.20371.
55. Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-8.
56. Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7, doi:10.1016/S0140-6736(02)08213-2.
57. Micha R, Imamura F, Wyler von BM, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011;108:1362-70, doi:10.1016/j.amjcard. 2011.06.054.
58. Myasoedova E, Crowson CS, Nicola PJ, et al. The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol 2011;38:1601-6, doi:10.3899/jrheum.100979.
59. Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010;49:295-307, doi:10.1093/ rheumatology/kep366.
60. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009;25:567- 79, doi:10.1016/S0828-282X(09)70715-9.
61. Friedewald VE, Cather JC, Gelfand JM, et al. AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol 2008;102:1631-43, doi:10.1016/j.amjcard.2008.10.004.
62. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008;58: 1031-42, doi:10.1016/j.jaad.2008.01.006.
63. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106:388-91, doi:10.1161/01.CIR. 0000020190.45892.75.
64. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39, doi:10.1161/01.CIR.0000133317.49796.0E.
65. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidencebased recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31, doi:10.1136/ard.2009.113696.
66. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-53, doi: 10.1161/CIRCULATIONAHA.107.699579.
67. Abe Y, Rundek T, Sciacca RR, et al. Ultrasound assessment of subclinical cardiovascular disease in a community-based multiethnic population and comparison to the Framingham score. Am J Cardiol 2006;98:1374-8, doi:10.1016/j.amjcard.2006.06.034.
68. Aviles-Santa L, Salinas K, Adams-Huet B, et al. Anthropometric features and cardiovascular risk in young Latin Americans with type 2 diabetes mellitus. J Diabetes Complications 2006;20:69-74, doi:10.1016/j.jdiacomp.2005.09.001.
69. Lee GK, Lee LC, Liu CW, et al. Framingham risk score inadequately predicts cardiac risk in young patients presenting with a first myocardial infarction. Ann Acad Med Singapore 2010; 39:163-7.
70. Zarich S, Luciano C, Hulford J, et al. Prevalence of metabolic syndrome in young patients with acute MI: does the Framingham Risk Score underestimate cardiovascular risk in this population? Diab Vasc Dis Res 2006;3:103-7, doi:10.3132/dvdr.2006.012.
71. Statistics Canada. Canadian Community Health Survey. 2011. The Daily. Available at: http://www.statcan.gc.ca/daily-quotidien/110621/dq110621b-eng.htm (accessed March 20, 2012).
72. Hulley SB, Cummings SR, Browner WS, et al, Designing clinical research. 2nd ed. Philadelphia: LippincottWilliams & Wilkins; 2001.
73. Spruance SL, Reid JE, Grace M, et al. Hazard ratio in clinical trials. Antimicrob Agents Chemother 2004;48:2787-92, doi:10.1128/AAC.48.8.2787-2792. 2004.
74. Copeland KT, Checkoway H, McMichael AJ, et al. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol 1977;105:488-95.
75. Katz MH. Multivariable analysis: a primer for readers of medical research. Ann Intern Med 2003;138:644-50.
76. Schechtman E. Odds ratio, relative risk, absolute risk reduction, and the number needed to treat - which of these should we use? Value Health 2002;5:431-6, doi:10.1046/J.1524-4733.2002.55150.x.
77. Benichou J, Palta M. Concepts and methodological approaches in epidemiology. In: Pigeot I, Ahrens W, editors. Handbook of epidemiology. Berlin: Springer; 2005. p. 112.
78. Haut ER, Pronovost PJ. Surveillance bias in outcomes reporting. JAMA 2011;305:2462-3, doi:10.1001/jama.2011.822.
79. Cohen AD, Gilutz H, Henkin Y, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007;87:506-9, doi:10.2340/00015555-0297.
80. Cohen AD, Dreiher J, Shapiro Y, et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 2008;22:585-9, doi:10.1111/j.1468-3083.2008.02636.x.
81. Cohen AD, Weitzman D, Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol 2010;90:23-6, doi:10.2340/00015555-0741.
82. Dreiher J, Weitzman D, Davidovici B, et al. Psoriasis and dyslipidaemia: a population-based study. Acta Derm Venereol 2008;88:561-5.
83. Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007;143:1559- 65, doi:10.1001/archderm.143.12.1559.
84. Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol Venereol Leprol 2010;76:662-5, doi:10.4103/0378- 6323.72462.
85. Qureshi AA, Choi HK, Setty AR, et al. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009;145:379-82, doi:10.1001/archdermatol.2009. 48.
86. Shapiro J, Cohen AD, David M, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a casecontrol study. J Am Acad Dermatol 2007;56:629-34, doi:10.1016/j.jaad.2006.09.017.
87. Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321-8, doi:10.1007/s00403- 006-0703-z.
88. Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol 2011. [Epub ahead of print]
89. Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010;163:586-92, doi:10.1111/j.1365- 2133.2010.09941.x.
90. Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011;270:147-57, doi:10.1111/j.1365- 2796.2010.02310.x.